[1]
National Center for Health Statistics, Centers for Disease Control and Prevention. (2013) Summary Health Statistics for the U.S. Population: National Health Interview Survey, 2012. Available at.
http://www.cdc.gov/nchs/data/series/sr_10/sr10_259.pdf.
[2]
Global status report on noncommunicable diseases 2014. WHO. 2014 Available at.. http://www.who.int/nmh/publications/ncd-status-report-2014/en/
[3]
Pirozzi, F.; Ren, K.; Murabito, A.; Ghigo, A. PI3K signaling in chronic obstructive pulmonary disease: mechanisms, targets, and therapy. Curr. Med. Chem., 2019, 26(16), 2791-2800. [http://dx.doi.org/10.2174/0929867325666180320120054]. [PMID: 29557740].
[4]
Damilano, F.; Franco, I.; Perrino, C.; Schaefer, K.; Azzolino, O.; Carnevale, D.; Cifelli, G.; Carullo, P.; Ragona, R.; Ghigo, A.; Perino, A.; Lembo, G.; Hirsch, E. Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase γ activity in pressure overload-induced cardiac failure. Circulation, 2011, 123(4), 391-399. [http://dx.doi.org/10.1161/CIRCULATIONAHA.110.950543]. [PMID: 21242482].
[5]
Ghigo, A.; Perino, A.; Mehel, H.; Zahradníková, A., Jr; Morello, F.; Leroy, J.; Nikolaev, V.O.; Damilano, F.; Cimino, J.; De Luca, E.; Richter, W.; Westenbroek, R.; Catterall, W.A.; Zhang, J.; Yan, C.; Conti, M.; Gomez, A.M.; Vandecasteele, G.; Hirsch, E.; Fischmeister, R. Phosphoinositide 3-kinase γ protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation, 2012, 126(17), 2073-2083. [http://dx.doi.org/10.1161/CIRCULATIONAHA.112.114074]. [PMID: 23008439].
[6]
Ghigo, A.; Morello, F.; Perino, A.; Hirsch, E. Therapeutic applications of PI3K inhibitors in cardiovascular diseases. Future Med. Chem., 2013, 5(4), 479-492. [http://dx.doi.org/10.4155/fmc.13.11]. [PMID: 23495693].
[7]
Li, M.; Sala, V.; De Santis, M.C.; Cimino, J.; Cappello, P.; Pianca, N.; Di Bona, A.; Margaria, J.P.; Martini, M.; Lazzarini, E.; Pirozzi, F.; Rossi, L.; Franco, I.; Bornbaum, J.; Heger, J.; Rohrbach, S.; Perino, A.; Tocchetti, C.G.; Lima, B.H.F.; Teixeira, M.M.; Porporato, P.E.; Schulz, R.; Angelini, A.; Sandri, M.; Ameri, P.; Sciarretta, S.; Lima-Júnior, R.C.P.; Mongillo, M.; Zaglia, T.; Morello, F.; Novelli, F.; Hirsch, E. Ghigo, A phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation, 2018, 138(7), 696-711. [http://dx.doi: 10.1161/CIRCULATIONAHA.117.030352]. [PMID: 29348263].
[8]
Varricchi, G.; Marone, G.; Spadaro, G.; Russo, M.; Granata, F.; Genovese, A.; Marone, G. Novel Biological Therapies in Severe Asthma: Targeting the Right Trait. Curr. Med. Chem., 2019, 26(16), 2801-2822. [http://dx.doi.org/10.2174/0929867325666180110094542]. [PMID: 29318959].
[9]
Rivellese, F.; Lobasso, A.; Barbieri, L.; Liccardo, B.; De Paulis, A.; Rossi, F.W. Novel therapeutic approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors. Curr. Med. Chem., 2019, 26(16), 2823-2843. [http://dx.doi.org/10.2174/0929867325666180209145243]. [PMID: 29424301].
[10]
Mukherjee, M.; Mercurio, V.; Tedford, R.J.; Shah, A.A.; Hsu, S.; Mullin, C.J.; Sato, T.; Damico, R.; Kolb, T.M.; Mathai, S.C.; Hassoun, P.M. Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. Eur. Respir. J., 2017, 50(5)1701436 [http://dx.doi.org/10.1183/13993003.01436-2017]. [PMID: 29167303].
[11]
Mercurio, V.; Mukherjee, M.; Tedford, R.J.; Zamanian, R.T.; Khair, R.M.; Sato, T.; Minai, O.A.; Torres, F.; Girgis, R.E.; Chin, K.; Damico, R.; Kolb, T.M.; Mathai, S.C.; Hassoun, P.M. Improvement in right ventricular strain with ambrisentan and tadalafil upfront therapy in scleroderma-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med., 2018, 197(3), 388-391. [http://dx.doi.org/10.1164/rccm.201704-0789LE]. [PMID: 28661697].
[12]
Bourji, K.I.; Kelemen, B.W.; Mathai, S.C.; Damico, R.L.; Kolb, T.M.; Mercurio, V.; Cozzi, F.; Tedford, R.J.; Hassoun, P.M. Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. Pulm. Circ., 2017, 7(2), 409-420. [http://dx.doi.org/10.1177/2045893217700438]. [PMID: 28597765].
[13]
Mercurio, V.; Bianco, A.; Campi, G.; Cuomo, A.; Diab, N.; Mancini, A.; Parrella, P.; Petretta, M.; Hassoun, P.; Bonaduce, D. New drugs, therapeutic strategies, and future direction for the treatment of Pulmonary Arterial Hypertension. Curr. Med. Chem., 2019, 26(16), 2844-2864. [http://dx.doi.org/10.2174/0929867325666180201095743]. [PMID: 29421995].
[14]
Ablasser, K.; Verheyen, N.; Glantschnig, T.; Agnetti, G.; Rainer, P.P. Unfolding Cardiac Amyloidosis - From Pathophysiology to Cure. Curr. Med. Chem., 2019, 26(16), 2865-2878. [http://dx.doi.org/10.2174/0929867325666180104153338]. [PMID: 29303069].
[15]
Rainer, P.P.; Dong, P.; Sorge, M.; Fert-Bober, J.; Holewinski, R.J.; Wang, Y.; Foss, C.A.; An, S.S.; Baracca, A.; Solaini, G.; Glabe, C.G.; Pomper, M.G.; Van Eyk, J.E.; Tomaselli, G.F.; Paolocci, N.; Agnetti, G. Desmin Phosphorylation Triggers Preamyloid Oligomers Formation and Myocyte Dysfunction in Acquired Heart Failure. Circ. Res., 2018, 122(10), e75-e83. [http://dx.doi.org/10.1161/CIRCRESAHA.117.312082]. [PMID: 29483093].
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
21
10
1
1